Results 191 to 200 of about 1,392 (217)

Isolation of actinium-225 for medical purposes

Radiochemistry, 2015
A procedure is described for isolation and purification of 225Ac as a 229Th daughter decay product using ion exchange. The process includes the following steps: separation of 229Th from a mixture of 225Ac and 225Ra (225Ac precursor) using an anion-exchange resin; separation of 225Ac and 225Ra using a cation-exchange resin; purification of 225Ac to ...
A. A. Kotovskii, N. A. Nerozin, I. V. Prokof’ev, V. V. Shapovalov, Yu. A. Yakovshchits, A. S. Bolonkin, A. V. Dunin   +6 more
openaire   +1 more source

Production of actinium-225 for alpha particle mediated radioimmunotherapy

Applied Radiation and Isotopes, 2005
The initial clinical trials for treatment of acute myeloid leukemia have demonstrated the effectiveness of the alpha emitter (213)Bi in killing cancer cells. Bismuth-213 is obtained from a radionuclide generator system from decay of 10-days (225)Ac parent.
Rose A, Boll, Dairin, Malkemus, Saed, Mirzadeh   +2 more
openaire   +2 more sources

Improved in Vivo Stability of Actinium-225 Macrocyclic Complexes

Journal of Medicinal Chemistry, 1999
The favorable nuclear properties of actinium-225 ((225)Ac) have led to proposal of this isotope for use in radioimmunotherapy. In an effort to reduce the toxicity of free (225)Ac, a series of ligands were evaluated for stability in vivo. Loss of (225)Ac from acyclic chelating agents resulted in high liver uptake and poor whole body clearance.
K A, Deal, I A, Davis, S, Mirzadeh, S J, Kennel, M W, Brechbiel   +4 more
openaire   +2 more sources

Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?

European Urology, 2021
Optimisation of prostate-specific membrane antigen (PSMA) based radioligand therapy (RLT) requires a focus on prospective trials.
Nattakorn Dhiantravan, Michael S. Hofman, Aravind S. Ravi Kumar   +2 more
openaire   +2 more sources

Carboxylate-derived calixarenes with high selectivity for actinium-225

Chemical Communications, 1998
The binding properties of two ligands, 5,11,17,23-tetra-tert-butyl-25,26,27,28-tetrakis(carboxymethoxy)calix[4]arene 1 and 5,11,17,23,29,35-hexa-tert-butyl-37,38,39,40,41,42- hexakiscarboxymethoxy)calix[6]arene 2, which show high selectivity for 225Ac3+ (an α-emitter with t1/2 = 10 days) over Na+, K+, Mg2+, Ca2+ and Zn2+ are described.
Xiaoyuan Chen, Min Ji, Chien M. Wai, Xiaoyuan Chen, Darrell R. Fisher   +4 more
openaire   +1 more source

NorthStar Perspectives for Actinium-225 Production at Commercial Scale

Current Radiopharmaceuticals, 2018
Actinium-225, and its daughter Bismuth-213, have great promise in Alpha Immuno Therapy (AIT) for treatment of various disease modalities. Unfortunately, current production levels of actinium-225 do not support broad use of either actinium-225 or bismuth-213 in development or use for disease treatment.
openaire   +2 more sources

Actinium-225 Conjugates of MAb CC49 and Humanized ΔCH₂CC49

Cancer Biotherapy and Radiopharmaceuticals, 2002
Radioisotopes with moderate half-lives are essential for conventional radioimmunotherapy using tumor-selective MAbs which require days for localization. Actinium-225, with a half-life of 10 days and a yield of 4 alpha particles in its decay chain, may be an ideal choice for tumor-targeted radioimmunotherapy.
Stephen J, Kennel, Martin W, Brechbiel, Diane E, Milenic, Jeffrey, Schlom, Saed, Mirzadeh   +4 more
openaire   +2 more sources

Growth and decay tables for radium-225 and actinium-225

Journal of Radioanalytical Chemistry, 1970
To facilitate the use of225Ra as a yield tracer in radiochemical assays of226Ra and228Ra, growth and decay tables for225Ra, and its daughter225Ac, have been computed.
K. A. Smith, B. O. Bartlett
openaire   +1 more source

Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand

Journal of Labelled Compounds and Radiopharmaceuticals, 2019
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer. The use of alpha emitters for cancer therapy has two distinct advantages over conventional therapies. The short range of alpha radiation in human tissue (less than 0.1 mm), corresponding to only a few cell diameters, allows selective killing of targeted cancer cells while
Frank Bruchertseifer, Alban Kellerbauer, Rikard Malmbeck, Alfred Morgenstern   +3 more
openaire   +2 more sources

ChemInform Abstract: Carboxylate‐Derived Calixarenes with High Selectivity for Actinium‐225.

ChemInform, 1998
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
X. CHEN, M. JI, D. R. FISHER, C. M. WAI
openaire   +1 more source